Quality of Life of Prostate Cancer Patients Treated with Androgen Deprivation Therapy in Ain Shams University Hospital

Abstract Background Prostate cancer is the second most common cancer in men worldwide, according to data from the World Health Organization (WHO) GLOBOCAN Database. The current lifetime risk of prostate cancer for men living in the United States is estimated to be approximately one in eight. In Egypt according to GLOBOCAN number of new cases of prostate cancer 4767 (7.2%), while 5-syear survival 97.5%. Aim of the Work In this study, we aimed to evaluate the impact of treatment with Androgen Deprivation Therapy on quality of life for prostate cancer patient treated in Ain Shams University Hospital using a questionnaire from European organization of research and treatment -quality of life for cancer patient – prostate (PR 25) on prostate patient an Arabic index validated. Patients and Methods This Cross-sectional study was conducted at tertiary care hospital at Ain Shams University hospitals from August 2022 to February 2023 and performed on a total of 45 prostate cancer patients who attended the outpatient clinic at oncology department at Ain Shams University for hormonal therapy that were diagnosed before 2021. Results Our study results revealed that there was no statistically significant correlation between the quality-of-life (QOL) scores and both age of patient and duration of hormonal treatment. In correlation with the demographic characteristics, our study results revealed that the symptom scale score and Functional scale score showed no statistically significant differences with the medical, surgical history of the patient, history of chemotherapy and radiotherapy, ECOG and Metastasis. Conclusion The quality-of-life scores (QLQ-PR25) revealed that the mean symptom scale was 41.11 (SD ± 10.94) and the functional scale was 67.22 (SD ± 13.86) with no significant correlation with both age of patient and duration of hormonal treatment. However, the study was single arm and lack the control group which may underestimate the sexual and urinary changes or outcomes due to the intervention by ADT in patients with prostate cancer. Consequently, the present study can burden the knowledge and shed some light on future prospective studies with larger sample sizes and control group demonstrating the long-term outcomes of ADT in patients with prostate cancer regarding the HR-QOL.